Can We Better Predict Who Is Most Likely to Have Another VTE After a First Event? – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Eugenia Biguzzi, adding:
”Can we better predict who is most likely to have another VTE after a first event?
A new RPTH study suggests that combining d-dimer with thrombin generation may improve risk stratification for recurrent venous thromboembolism. In this cohort of 1,895 patients, recurrence risk was lowest in those with low d-dimer + low thrombin generation, intermediate when only 1 marker was elevated, and highest when both were elevated.
The signal was especially striking in unprovoked VTE. Patients with high d-dimer and high thrombin generation had an incidence rate of 9.80 per 100 patient-years, compared with 1.36 per 100 patient-years in those with low levels of both markers, with an adjusted hazard ratio of 8.59.
Why this matters:
Extending anticoagulation lowers recurrence risk, but bleeding risk remains the tradeoff. Tools that better separate low-, intermediate-, and high-risk patients could help guide more personalized decisions after a first VTE.
A key caveat: thrombin generation was measured with a specialized assay, which may limit immediate routine clinical use. Still, this study adds to the push toward biomarker-guided anticoagulation decisions rather than relying on broad clinical categories alone.”
Title: Recurrent venous thromboembolism: association with thrombin generation and d-dimer
Authors: Eugenia Biguzzi, Kristien Winckers, Tilman M. Hackeng, Frits R. Rosendaal, Astrid van Hylckama Vlieg
Read the Full Article on RPTH
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026